United Therapeutics Corporation (NASDAQ: UTHR) Stock Competitors & Peer Comparison
See UTHR's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for UTHR and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| UTHR | $497.11 | -1.34% | 21.1B | 17.79 | $27.95 | N/A |
| VRTX | $515.44 | +0.17% | 130.8B | 27.09 | $19.03 | N/A |
| REGN | $781.49 | -1.48% | 80.5B | 17.13 | $45.63 | +0.47% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $984.39 | +0.04% | 61.2B | 88.84 | $11.08 | N/A |
| MRNA | $143.97 | +5.38% | 57.1B | -17.67 | -$8.15 | N/A |
| RVMDW | $11.29 | +2.08% | 44.2B | -1.28 | -$8.82 | N/A |
| RVMD | $203.77 | +0.21% | 43.3B | -23.10 | -$8.82 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ONC | $346.51 | +1.38% | 37B | 61.01 | $5.68 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
UTHR vs VRTX Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, VRTX has a market cap of 130.8B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while VRTX trades at $515.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas VRTX's P/E ratio is 27.09. In terms of profitability, UTHR's ROE is +0.20%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, UTHR is more volatile compared to VRTX. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check VRTX's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
UTHR vs REGN Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, REGN has a market cap of 80.5B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while REGN trades at $781.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas REGN's P/E ratio is 17.13. In terms of profitability, UTHR's ROE is +0.20%, compared to REGN's ROE of +0.14%. Regarding short-term risk, UTHR is more volatile compared to REGN. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check REGN's competition here
Verona Pharma plc (NASDAQ: VRNA)
UTHR vs VRNA Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas VRNA's P/E ratio is -102.80. In terms of profitability, UTHR's ROE is +0.20%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, UTHR is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check VRNA's competition here
argenx SE (NASDAQ: ARGX)
UTHR vs ARGX Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, ARGX has a market cap of 61.2B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while ARGX trades at $984.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas ARGX's P/E ratio is 88.84. In terms of profitability, UTHR's ROE is +0.20%, compared to ARGX's ROE of +0.24%. Regarding short-term risk, UTHR is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check ARGX's competition here
Moderna, Inc. (NASDAQ: MRNA)
UTHR vs MRNA Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, MRNA has a market cap of 57.1B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while MRNA trades at $143.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas MRNA's P/E ratio is -17.67. In terms of profitability, UTHR's ROE is +0.20%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, UTHR is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for UTHR.Check MRNA's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
UTHR vs RVMDW Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, RVMDW has a market cap of 44.2B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while RVMDW trades at $11.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas RVMDW's P/E ratio is -1.28. In terms of profitability, UTHR's ROE is +0.20%, compared to RVMDW's ROE of -0.96%. Regarding short-term risk, UTHR is less volatile compared to RVMDW. This indicates lower risk in terms of short-term price fluctuations for UTHR.Check RVMDW's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
UTHR vs RVMD Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, RVMD has a market cap of 43.3B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while RVMD trades at $203.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas RVMD's P/E ratio is -23.10. In terms of profitability, UTHR's ROE is +0.20%, compared to RVMD's ROE of -0.96%. Regarding short-term risk, UTHR is less volatile compared to RVMD. This indicates lower risk in terms of short-term price fluctuations for UTHR.Check RVMD's competition here
Seagen Inc. (NASDAQ: SGEN)
UTHR vs SGEN Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas SGEN's P/E ratio is -57.19. In terms of profitability, UTHR's ROE is +0.20%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, UTHR is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check SGEN's competition here
BeOne Medicines AG (NASDAQ: ONC)
UTHR vs ONC Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, ONC has a market cap of 37B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while ONC trades at $346.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas ONC's P/E ratio is 61.01. In terms of profitability, UTHR's ROE is +0.20%, compared to ONC's ROE of +0.14%. Regarding short-term risk, UTHR is more volatile compared to ONC. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check ONC's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
UTHR vs ALNY Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, ALNY has a market cap of 33.3B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while ALNY trades at $248.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas ALNY's P/E ratio is 44.81. In terms of profitability, UTHR's ROE is +0.20%, compared to ALNY's ROE of +0.94%. Regarding short-term risk, UTHR is less volatile compared to ALNY. This indicates lower risk in terms of short-term price fluctuations for UTHR.Check ALNY's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
UTHR vs ROIV Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, ROIV has a market cap of 29.5B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while ROIV trades at $40.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas ROIV's P/E ratio is -38.82. In terms of profitability, UTHR's ROE is +0.20%, compared to ROIV's ROE of -0.06%. Regarding short-term risk, UTHR is less volatile compared to ROIV. This indicates lower risk in terms of short-term price fluctuations for UTHR.Check ROIV's competition here
Insmed Incorporated (NASDAQ: INSM)
UTHR vs INSM Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, INSM has a market cap of 28B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while INSM trades at $129.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas INSM's P/E ratio is -31.49. In terms of profitability, UTHR's ROE is +0.20%, compared to INSM's ROE of -1.11%. Regarding short-term risk, UTHR is less volatile compared to INSM. This indicates lower risk in terms of short-term price fluctuations for UTHR.Check INSM's competition here
Incyte Corporation (NASDAQ: INCY)
UTHR vs INCY Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, INCY has a market cap of 24.6B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while INCY trades at $121.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas INCY's P/E ratio is 16.33. In terms of profitability, UTHR's ROE is +0.20%, compared to INCY's ROE of +0.30%. Regarding short-term risk, UTHR is more volatile compared to INCY. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check INCY's competition here
BioNTech SE (NASDAQ: BNTX)
UTHR vs BNTX Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, BNTX has a market cap of 24.3B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while BNTX trades at $96.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas BNTX's P/E ratio is -12.54. In terms of profitability, UTHR's ROE is +0.20%, compared to BNTX's ROE of -0.09%. Regarding short-term risk, UTHR is more volatile compared to BNTX. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check BNTX's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
UTHR vs BGNE Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas BGNE's P/E ratio is -22.55. In terms of profitability, UTHR's ROE is +0.20%, compared to BGNE's ROE of +0.14%. Regarding short-term risk, UTHR is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check BGNE's competition here
Genmab A/S (NASDAQ: GMAB)
UTHR vs GMAB Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, GMAB has a market cap of 19.9B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while GMAB trades at $32.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas GMAB's P/E ratio is 24.47. In terms of profitability, UTHR's ROE is +0.20%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, UTHR is more volatile compared to GMAB. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check GMAB's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
UTHR vs DNA-WT Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, UTHR's ROE is +0.20%, compared to DNA-WT's ROE of -0.60%. Regarding short-term risk, UTHR is less volatile compared to DNA-WT. This indicates lower risk in terms of short-term price fluctuations for UTHR.Check DNA-WT's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
UTHR vs ASND Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, ASND has a market cap of 16.4B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while ASND trades at $263.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas ASND's P/E ratio is -108.89. In terms of profitability, UTHR's ROE is +0.20%, compared to ASND's ROE of +1.90%. Regarding short-term risk, UTHR is less volatile compared to ASND. This indicates lower risk in terms of short-term price fluctuations for UTHR.Check ASND's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
UTHR vs NBIX Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, NBIX has a market cap of 15.7B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while NBIX trades at $156.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas NBIX's P/E ratio is 22.57. In terms of profitability, UTHR's ROE is +0.20%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, UTHR is more volatile compared to NBIX. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check NBIX's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
UTHR vs JAZZ Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, JAZZ has a market cap of 15.4B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while JAZZ trades at $245.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas JAZZ's P/E ratio is 9.16. In terms of profitability, UTHR's ROE is +0.20%, compared to JAZZ's ROE of +0.21%. Regarding short-term risk, UTHR is more volatile compared to JAZZ. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check JAZZ's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
UTHR vs BBIO Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, BBIO has a market cap of 14.2B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while BBIO trades at $72.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas BBIO's P/E ratio is -19.37. In terms of profitability, UTHR's ROE is +0.20%, compared to BBIO's ROE of +0.32%. Regarding short-term risk, UTHR is less volatile compared to BBIO. This indicates lower risk in terms of short-term price fluctuations for UTHR.Check BBIO's competition here
Exelixis, Inc. (NASDAQ: EXEL)
UTHR vs EXEL Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, EXEL has a market cap of 14.1B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while EXEL trades at $56.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas EXEL's P/E ratio is 16.03. In terms of profitability, UTHR's ROE is +0.20%, compared to EXEL's ROE of +0.42%. Regarding short-term risk, UTHR is less volatile compared to EXEL. This indicates lower risk in terms of short-term price fluctuations for UTHR.Check EXEL's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
UTHR vs SMMT Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, SMMT has a market cap of 14B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while SMMT trades at $17.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas SMMT's P/E ratio is -15.67. In terms of profitability, UTHR's ROE is +0.20%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, UTHR is less volatile compared to SMMT. This indicates lower risk in terms of short-term price fluctuations for UTHR.Check SMMT's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
UTHR vs HALO Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, HALO has a market cap of 12.7B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while HALO trades at $107.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas HALO's P/E ratio is 20.00. In terms of profitability, UTHR's ROE is +0.20%, compared to HALO's ROE of +1.81%. Regarding short-term risk, UTHR is more volatile compared to HALO. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check HALO's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
UTHR vs BMRN Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, BMRN has a market cap of 12.7B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while BMRN trades at $65.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas BMRN's P/E ratio is 31.58. In terms of profitability, UTHR's ROE is +0.20%, compared to BMRN's ROE of +0.01%. Regarding short-term risk, UTHR is more volatile compared to BMRN. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check BMRN's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
UTHR vs KRTX Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas KRTX's P/E ratio is -28.09. In terms of profitability, UTHR's ROE is +0.20%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, UTHR is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check KRTX's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
UTHR vs MDGL Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, MDGL has a market cap of 12.3B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while MDGL trades at $534.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas MDGL's P/E ratio is -41.76. In terms of profitability, UTHR's ROE is +0.20%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, UTHR is less volatile compared to MDGL. This indicates lower risk in terms of short-term price fluctuations for UTHR.Check MDGL's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
UTHR vs ARWR Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, ARWR has a market cap of 11.7B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while ARWR trades at $82.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas ARWR's P/E ratio is -36.82. In terms of profitability, UTHR's ROE is +0.20%, compared to ARWR's ROE of -0.61%. Regarding short-term risk, UTHR is less volatile compared to ARWR. This indicates lower risk in terms of short-term price fluctuations for UTHR.Check ARWR's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
UTHR vs AXSM Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, AXSM has a market cap of 11.4B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while AXSM trades at $220.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas AXSM's P/E ratio is -57.64. In terms of profitability, UTHR's ROE is +0.20%, compared to AXSM's ROE of -2.56%. Regarding short-term risk, UTHR is less volatile compared to AXSM. This indicates lower risk in terms of short-term price fluctuations for UTHR.Check AXSM's competition here
Bio-Techne Corporation (NASDAQ: TECH)
UTHR vs TECH Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, TECH has a market cap of 11.3B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while TECH trades at $72.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas TECH's P/E ratio is 37.18. In terms of profitability, UTHR's ROE is +0.20%, compared to TECH's ROE of +0.09%. Regarding short-term risk, UTHR is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check TECH's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
UTHR vs RNAM Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas RNAM's P/E ratio is -17.39. In terms of profitability, UTHR's ROE is +0.20%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, UTHR is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check RNAM's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
UTHR vs KRYS Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, KRYS has a market cap of 10.2B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while KRYS trades at $347.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas KRYS's P/E ratio is 43.48. In terms of profitability, UTHR's ROE is +0.20%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, UTHR is more volatile compared to KRYS. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check KRYS's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
UTHR vs RXDX Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas RXDX's P/E ratio is -56.47. In terms of profitability, UTHR's ROE is +0.20%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, UTHR is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check RXDX's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
UTHR vs PTGX Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, PTGX has a market cap of 9.5B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while PTGX trades at $148.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas PTGX's P/E ratio is 143.86. In terms of profitability, UTHR's ROE is +0.20%, compared to PTGX's ROE of +0.12%. Regarding short-term risk, UTHR is less volatile compared to PTGX. This indicates lower risk in terms of short-term price fluctuations for UTHR.Check PTGX's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
UTHR vs KYMR Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, KYMR has a market cap of 9.5B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while KYMR trades at $114.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas KYMR's P/E ratio is -35.92. In terms of profitability, UTHR's ROE is +0.20%, compared to KYMR's ROE of -0.22%. Regarding short-term risk, UTHR is less volatile compared to KYMR. This indicates lower risk in terms of short-term price fluctuations for UTHR.Check KYMR's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
UTHR vs PRAX Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, PRAX has a market cap of 9.3B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while PRAX trades at $334.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas PRAX's P/E ratio is -25.88. In terms of profitability, UTHR's ROE is +0.20%, compared to PRAX's ROE of -0.34%. Regarding short-term risk, UTHR is less volatile compared to PRAX. This indicates lower risk in terms of short-term price fluctuations for UTHR.Check PRAX's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
UTHR vs CYTK Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, CYTK has a market cap of 9.2B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while CYTK trades at $73.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas CYTK's P/E ratio is -10.22. In terms of profitability, UTHR's ROE is +0.20%, compared to CYTK's ROE of +1.64%. Regarding short-term risk, UTHR is less volatile compared to CYTK. This indicates lower risk in terms of short-term price fluctuations for UTHR.Check CYTK's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
UTHR vs NUVL Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas NUVL's P/E ratio is -21.79. In terms of profitability, UTHR's ROE is +0.20%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, UTHR is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check NUVL's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
UTHR vs IONS Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, IONS has a market cap of 9B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while IONS trades at $54.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas IONS's P/E ratio is -31.52. In terms of profitability, UTHR's ROE is +0.20%, compared to IONS's ROE of -1.11%. Regarding short-term risk, UTHR is less volatile compared to IONS. This indicates lower risk in terms of short-term price fluctuations for UTHR.Check IONS's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
UTHR vs CRNX Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, CRNX has a market cap of 9B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while CRNX trades at $84.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas CRNX's P/E ratio is -16.86. In terms of profitability, UTHR's ROE is +0.20%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, UTHR is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check CRNX's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
UTHR vs IMGN Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas IMGN's P/E ratio is -111.55. In terms of profitability, UTHR's ROE is +0.20%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, UTHR is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check IMGN's competition here
Abivax S.A. (NASDAQ: ABVX)
UTHR vs ABVX Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, ABVX has a market cap of 8.7B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while ABVX trades at $118.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas ABVX's P/E ratio is -62.19. In terms of profitability, UTHR's ROE is +0.20%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, UTHR is less volatile compared to ABVX. This indicates lower risk in terms of short-term price fluctuations for UTHR.Check ABVX's competition here
10x Genomics, Inc. (NASDAQ: TXG)
UTHR vs TXG Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, TXG has a market cap of 8.7B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while TXG trades at $68.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas TXG's P/E ratio is -116.25. In terms of profitability, UTHR's ROE is +0.20%, compared to TXG's ROE of -0.09%. Regarding short-term risk, UTHR is less volatile compared to TXG. This indicates lower risk in terms of short-term price fluctuations for UTHR.Check TXG's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
UTHR vs PCVX Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, PCVX has a market cap of 8.6B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while PCVX trades at $59.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas PCVX's P/E ratio is -7.79. In terms of profitability, UTHR's ROE is +0.20%, compared to PCVX's ROE of -0.38%. Regarding short-term risk, UTHR is less volatile compared to PCVX. This indicates lower risk in terms of short-term price fluctuations for UTHR.Check PCVX's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
UTHR vs BPMC Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas BPMC's P/E ratio is -51.58. In terms of profitability, UTHR's ROE is +0.20%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, UTHR is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check BPMC's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
UTHR vs APGE Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, APGE has a market cap of 8.4B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while APGE trades at $135.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas APGE's P/E ratio is -31.19. In terms of profitability, UTHR's ROE is +0.20%, compared to APGE's ROE of -0.30%. Regarding short-term risk, UTHR is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check APGE's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
UTHR vs IBRX Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, IBRX has a market cap of 8.3B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while IBRX trades at $7.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas IBRX's P/E ratio is -8.15. In terms of profitability, UTHR's ROE is +0.20%, compared to IBRX's ROE of +1.35%. Regarding short-term risk, UTHR is less volatile compared to IBRX. This indicates lower risk in terms of short-term price fluctuations for UTHR.Check IBRX's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
UTHR vs TGTX Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, TGTX has a market cap of 8.2B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while TGTX trades at $53.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas TGTX's P/E ratio is 19.53. In terms of profitability, UTHR's ROE is +0.20%, compared to TGTX's ROE of +0.72%. Regarding short-term risk, UTHR is less volatile compared to TGTX. This indicates lower risk in terms of short-term price fluctuations for UTHR.Check TGTX's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
UTHR vs CERE Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas CERE's P/E ratio is -16.47. In terms of profitability, UTHR's ROE is +0.20%, compared to CERE's ROE of -0.72%. Regarding short-term risk, UTHR is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check CERE's competition here
Twist Bioscience Corporation (NASDAQ: TWST)
UTHR vs TWST Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, TWST has a market cap of 7.9B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while TWST trades at $127.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas TWST's P/E ratio is -57.31. In terms of profitability, UTHR's ROE is +0.20%, compared to TWST's ROE of -0.30%. Regarding short-term risk, UTHR is less volatile compared to TWST. This indicates lower risk in terms of short-term price fluctuations for UTHR.Check TWST's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
UTHR vs SYRE Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, SYRE has a market cap of 7.9B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while SYRE trades at $90.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas SYRE's P/E ratio is -46.46. In terms of profitability, UTHR's ROE is +0.20%, compared to SYRE's ROE of -0.24%. Regarding short-term risk, UTHR is less volatile compared to SYRE. This indicates lower risk in terms of short-term price fluctuations for UTHR.Check SYRE's competition here
Immunovant, Inc. (NASDAQ: IMVT)
UTHR vs IMVT Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, IMVT has a market cap of 7.7B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while IMVT trades at $37.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas IMVT's P/E ratio is -13.25. In terms of profitability, UTHR's ROE is +0.20%, compared to IMVT's ROE of -0.70%. Regarding short-term risk, UTHR is less volatile compared to IMVT. This indicates lower risk in terms of short-term price fluctuations for UTHR.Check IMVT's competition here
Metsera, Inc. (NASDAQ: MTSR)
UTHR vs MTSR Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas MTSR's P/E ratio is -23.58. In terms of profitability, UTHR's ROE is +0.20%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, UTHR is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check MTSR's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
UTHR vs RYTM Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, RYTM has a market cap of 7.2B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while RYTM trades at $104.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas RYTM's P/E ratio is -33.67. In terms of profitability, UTHR's ROE is +0.20%, compared to RYTM's ROE of -0.80%. Regarding short-term risk, UTHR is less volatile compared to RYTM. This indicates lower risk in terms of short-term price fluctuations for UTHR.Check RYTM's competition here
Belite Bio, Inc (NASDAQ: BLTE)
UTHR vs BLTE Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, BLTE has a market cap of 7B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while BLTE trades at $173.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas BLTE's P/E ratio is -92.94. In terms of profitability, UTHR's ROE is +0.20%, compared to BLTE's ROE of -0.16%. Regarding short-term risk, UTHR is less volatile compared to BLTE. This indicates lower risk in terms of short-term price fluctuations for UTHR.Check BLTE's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
UTHR vs CAI Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, CAI has a market cap of 6.9B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while CAI trades at $24.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas CAI's P/E ratio is 68.39. In terms of profitability, UTHR's ROE is +0.20%, compared to CAI's ROE of +0.19%. Regarding short-term risk, UTHR is more volatile compared to CAI. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check CAI's competition here
Merus N.V. (NASDAQ: MRUS)
UTHR vs MRUS Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas MRUS's P/E ratio is -17.05. In terms of profitability, UTHR's ROE is +0.20%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, UTHR is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check MRUS's competition here
Arcellx, Inc. (NASDAQ: ACLX)
UTHR vs ACLX Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas ACLX's P/E ratio is -28.27. In terms of profitability, UTHR's ROE is +0.20%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, UTHR is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check ACLX's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
UTHR vs SRRK Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, SRRK has a market cap of 6.6B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while SRRK trades at $55.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas SRRK's P/E ratio is -16.06. In terms of profitability, UTHR's ROE is +0.20%, compared to SRRK's ROE of -1.60%. Regarding short-term risk, UTHR is less volatile compared to SRRK. This indicates lower risk in terms of short-term price fluctuations for UTHR.Check SRRK's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
UTHR vs RETA Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas RETA's P/E ratio is -66.29. In terms of profitability, UTHR's ROE is +0.20%, compared to RETA's ROE of +0.47%. Regarding short-term risk, UTHR is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check RETA's competition here
CG Oncology Inc. (NASDAQ: CGON)
UTHR vs CGON Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, CGON has a market cap of 6.4B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while CGON trades at $72.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas CGON's P/E ratio is -26.90. In terms of profitability, UTHR's ROE is +0.20%, compared to CGON's ROE of -0.25%. Regarding short-term risk, UTHR is less volatile compared to CGON. This indicates lower risk in terms of short-term price fluctuations for UTHR.Check CGON's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
UTHR vs CNTA Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas CNTA's P/E ratio is -22.63. In terms of profitability, UTHR's ROE is +0.20%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, UTHR is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check CNTA's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
UTHR vs TVTX Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, TVTX has a market cap of 6.2B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while TVTX trades at $66.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas TVTX's P/E ratio is -147.04. In terms of profitability, UTHR's ROE is +0.20%, compared to TVTX's ROE of -0.56%. Regarding short-term risk, UTHR is less volatile compared to TVTX. This indicates lower risk in terms of short-term price fluctuations for UTHR.Check TVTX's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
UTHR vs MIRM Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, MIRM has a market cap of 6B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while MIRM trades at $98.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas MIRM's P/E ratio is -6.75. In terms of profitability, UTHR's ROE is +0.20%, compared to MIRM's ROE of -4.10%. Regarding short-term risk, UTHR is less volatile compared to MIRM. This indicates lower risk in terms of short-term price fluctuations for UTHR.Check MIRM's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
UTHR vs DNTH Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, DNTH has a market cap of 5.9B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while DNTH trades at $106.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas DNTH's P/E ratio is -25.59. In terms of profitability, UTHR's ROE is +0.20%, compared to DNTH's ROE of -0.04%. Regarding short-term risk, UTHR is less volatile compared to DNTH. This indicates lower risk in terms of short-term price fluctuations for UTHR.Check DNTH's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
UTHR vs COGT Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, COGT has a market cap of 5.7B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while COGT trades at $33.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas COGT's P/E ratio is -15.83. In terms of profitability, UTHR's ROE is +0.20%, compared to COGT's ROE of -0.73%. Regarding short-term risk, UTHR is less volatile compared to COGT. This indicates lower risk in terms of short-term price fluctuations for UTHR.Check COGT's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
UTHR vs LGND Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, LGND has a market cap of 5.7B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while LGND trades at $284.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas LGND's P/E ratio is 31.23. In terms of profitability, UTHR's ROE is +0.20%, compared to LGND's ROE of +0.20%. Regarding short-term risk, UTHR is less volatile compared to LGND. This indicates lower risk in terms of short-term price fluctuations for UTHR.Check LGND's competition here
Xenon Pharmaceuticals Inc. (NASDAQ: XENE)
UTHR vs XENE Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, XENE has a market cap of 5.7B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while XENE trades at $58.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas XENE's P/E ratio is -12.48. In terms of profitability, UTHR's ROE is +0.20%, compared to XENE's ROE of -0.44%. Regarding short-term risk, UTHR is more volatile compared to XENE. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check XENE's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
UTHR vs CDTX Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas CDTX's P/E ratio is -19.77. In terms of profitability, UTHR's ROE is +0.20%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, UTHR is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check CDTX's competition here
Oruka Therapeutics, Inc. (NASDAQ: ORKA)
UTHR vs ORKA Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, ORKA has a market cap of 5.6B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while ORKA trades at $92.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas ORKA's P/E ratio is -47.62. In terms of profitability, UTHR's ROE is +0.20%, compared to ORKA's ROE of -0.21%. Regarding short-term risk, UTHR is less volatile compared to ORKA. This indicates lower risk in terms of short-term price fluctuations for UTHR.Check ORKA's competition here
Abcam plc (NASDAQ: ABCM)
UTHR vs ABCM Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, UTHR's ROE is +0.20%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, UTHR is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check ABCM's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
UTHR vs PTCT Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, PTCT has a market cap of 5.5B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while PTCT trades at $66.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas PTCT's P/E ratio is -28.35. In terms of profitability, UTHR's ROE is +0.20%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, UTHR is less volatile compared to PTCT. This indicates lower risk in terms of short-term price fluctuations for UTHR.Check PTCT's competition here
Erasca, Inc. (NASDAQ: ERAS)
UTHR vs ERAS Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, ERAS has a market cap of 5.5B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while ERAS trades at $15.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas ERAS's P/E ratio is -17.08. In terms of profitability, UTHR's ROE is +0.20%, compared to ERAS's ROE of -0.80%. Regarding short-term risk, UTHR is less volatile compared to ERAS. This indicates lower risk in terms of short-term price fluctuations for UTHR.Check ERAS's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
UTHR vs ISEE Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas ISEE's P/E ratio is -22.44. In terms of profitability, UTHR's ROE is +0.20%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, UTHR is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check ISEE's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
UTHR vs APLS Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas APLS's P/E ratio is 38.35. In terms of profitability, UTHR's ROE is +0.20%, compared to APLS's ROE of +0.40%. Regarding short-term risk, UTHR is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check APLS's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
UTHR vs DFTX Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, DFTX has a market cap of 5.2B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while DFTX trades at $38.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas DFTX's P/E ratio is N/A. In terms of profitability, UTHR's ROE is +0.20%, compared to DFTX's ROE of -0.85%. Regarding short-term risk, UTHR is less volatile compared to DFTX. This indicates lower risk in terms of short-term price fluctuations for UTHR.Check DFTX's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
UTHR vs CRSP Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, CRSP has a market cap of 5B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while CRSP trades at $51.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas CRSP's P/E ratio is -10.87. In terms of profitability, UTHR's ROE is +0.20%, compared to CRSP's ROE of -0.24%. Regarding short-term risk, UTHR is less volatile compared to CRSP. This indicates lower risk in terms of short-term price fluctuations for UTHR.Check CRSP's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
UTHR vs EWTX Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, EWTX has a market cap of 4.8B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while EWTX trades at $44.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas EWTX's P/E ratio is -24.00. In terms of profitability, UTHR's ROE is +0.20%, compared to EWTX's ROE of -0.39%. Regarding short-term risk, UTHR is less volatile compared to EWTX. This indicates lower risk in terms of short-term price fluctuations for UTHR.Check EWTX's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
UTHR vs TERN Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas TERN's P/E ratio is -51.41. In terms of profitability, UTHR's ROE is +0.20%, compared to TERN's ROE of -0.20%. Regarding short-term risk, UTHR is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check TERN's competition here
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD)
UTHR vs ACAD Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, ACAD has a market cap of 4.8B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while ACAD trades at $27.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas ACAD's P/E ratio is 12.54. In terms of profitability, UTHR's ROE is +0.20%, compared to ACAD's ROE of +0.32%. Regarding short-term risk, UTHR is more volatile compared to ACAD. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check ACAD's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
UTHR vs FOLD Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas FOLD's P/E ratio is -161.00. In terms of profitability, UTHR's ROE is +0.20%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, UTHR is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check FOLD's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
UTHR vs AKRO Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas AKRO's P/E ratio is -14.57. In terms of profitability, UTHR's ROE is +0.20%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, UTHR is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check AKRO's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
UTHR vs ALPN Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas ALPN's P/E ratio is -101.52. In terms of profitability, UTHR's ROE is +0.20%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, UTHR is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check ALPN's competition here
Parabilis Medicines, Inc. (NASDAQ: PBLS)
UTHR vs PBLS Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, PBLS has a market cap of 4.3B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while PBLS trades at $36.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas PBLS's P/E ratio is -41.91. In terms of profitability, UTHR's ROE is +0.20%, compared to PBLS's ROE of -0.15%. Regarding short-term risk, UTHR is less volatile compared to PBLS. This indicates lower risk in terms of short-term price fluctuations for UTHR.Check PBLS's competition here
Opthea Limited (NASDAQ: OPT)
UTHR vs OPT Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas OPT's P/E ratio is -1.52. In terms of profitability, UTHR's ROE is +0.20%, compared to OPT's ROE of +1.18%. Regarding short-term risk, UTHR is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check OPT's competition here
PureTech Health plc (NASDAQ: PRTC)
UTHR vs PRTC Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while PRTC trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas PRTC's P/E ratio is -3.78. In terms of profitability, UTHR's ROE is +0.20%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, UTHR is less volatile compared to PRTC. This indicates lower risk in terms of short-term price fluctuations for UTHR.Check PRTC's competition here
Veradermics, Incorporated (NYSE: MANE)
UTHR vs MANE Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, MANE has a market cap of 4.1B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while MANE trades at $98.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas MANE's P/E ratio is -31.52. In terms of profitability, UTHR's ROE is +0.20%, compared to MANE's ROE of -0.38%. Regarding short-term risk, UTHR is less volatile compared to MANE. This indicates lower risk in terms of short-term price fluctuations for UTHR.Check MANE's competition here
Relay Therapeutics, Inc. (NASDAQ: RLAY)
UTHR vs RLAY Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, RLAY has a market cap of 4.1B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while RLAY trades at $18.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas RLAY's P/E ratio is -12.02. In terms of profitability, UTHR's ROE is +0.20%, compared to RLAY's ROE of -0.42%. Regarding short-term risk, UTHR is less volatile compared to RLAY. This indicates lower risk in terms of short-term price fluctuations for UTHR.Check RLAY's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
UTHR vs MRTX Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas MRTX's P/E ratio is -4.82. In terms of profitability, UTHR's ROE is +0.20%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, UTHR is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check MRTX's competition here
Celcuity Inc. (NASDAQ: CELC)
UTHR vs CELC Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, CELC has a market cap of 4.1B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while CELC trades at $83.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas CELC's P/E ratio is -19.41. In terms of profitability, UTHR's ROE is +0.20%, compared to CELC's ROE of -3.51%. Regarding short-term risk, UTHR is less volatile compared to CELC. This indicates lower risk in terms of short-term price fluctuations for UTHR.Check CELC's competition here
Enliven Therapeutics, Inc. (NASDAQ: ELVN)
UTHR vs ELVN Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, ELVN has a market cap of 3.9B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while ELVN trades at $54.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas ELVN's P/E ratio is -32.53. In terms of profitability, UTHR's ROE is +0.20%, compared to ELVN's ROE of -0.19%. Regarding short-term risk, UTHR is less volatile compared to ELVN. This indicates lower risk in terms of short-term price fluctuations for UTHR.Check ELVN's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
UTHR vs ADPT Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, ADPT has a market cap of 3.9B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while ADPT trades at $24.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas ADPT's P/E ratio is -59.02. In terms of profitability, UTHR's ROE is +0.20%, compared to ADPT's ROE of -0.33%. Regarding short-term risk, UTHR is less volatile compared to ADPT. This indicates lower risk in terms of short-term price fluctuations for UTHR.Check ADPT's competition here
Tango Therapeutics, Inc. (NASDAQ: TNGX)
UTHR vs TNGX Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, TNGX has a market cap of 3.9B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while TNGX trades at $23.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas TNGX's P/E ratio is -28.65. In terms of profitability, UTHR's ROE is +0.20%, compared to TNGX's ROE of -0.26%. Regarding short-term risk, UTHR is less volatile compared to TNGX. This indicates lower risk in terms of short-term price fluctuations for UTHR.Check TNGX's competition here
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
UTHR vs CPRX Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas CPRX's P/E ratio is 12.30. In terms of profitability, UTHR's ROE is +0.20%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, UTHR is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check CPRX's competition here
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA)
UTHR vs IOVA Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, IOVA has a market cap of 3.8B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while IOVA trades at $8.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas IOVA's P/E ratio is -11.78. In terms of profitability, UTHR's ROE is +0.20%, compared to IOVA's ROE of -0.41%. Regarding short-term risk, UTHR is less volatile compared to IOVA. This indicates lower risk in terms of short-term price fluctuations for UTHR.Check IOVA's competition here
Telix Pharmaceuticals Limited (NASDAQ: TLX)
UTHR vs TLX Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, TLX has a market cap of 3.8B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while TLX trades at $11.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas TLX's P/E ratio is 117.85. In terms of profitability, UTHR's ROE is +0.20%, compared to TLX's ROE of +0.07%. Regarding short-term risk, UTHR is less volatile compared to TLX. This indicates lower risk in terms of short-term price fluctuations for UTHR.Check TLX's competition here
RayzeBio, Inc. Common Stock (NASDAQ: RYZB)
UTHR vs RYZB Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas RYZB's P/E ratio is -57.86. In terms of profitability, UTHR's ROE is +0.20%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, UTHR is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check RYZB's competition here
Viking Therapeutics, Inc. (NASDAQ: VKTX)
UTHR vs VKTX Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, VKTX has a market cap of 3.7B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while VKTX trades at $31.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas VKTX's P/E ratio is -6.86. In terms of profitability, UTHR's ROE is +0.20%, compared to VKTX's ROE of -0.95%. Regarding short-term risk, UTHR is less volatile compared to VKTX. This indicates lower risk in terms of short-term price fluctuations for UTHR.Check VKTX's competition here
CymaBay Therapeutics, Inc. (NASDAQ: CBAY)
UTHR vs CBAY Comparison September 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 21.1B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, UTHR is priced at $497.11 on the NASDAQ, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 17.79, whereas CBAY's P/E ratio is -32.81. In terms of profitability, UTHR's ROE is +0.20%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, UTHR is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check CBAY's competition here